RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity.

被引：0
|
作者：
Spigel, David R.
Paz-Ares, Luis G.
Chen, Yuanbin
Jove, Maria
Juan-Vidal, Oscar
Rich, Patricia
Hayes, Theresa M.
Calderon, M. Vanesa Gutierrez
Caro, Reyes Bernabe
Navarro, Alejandro
Dowlati, Afshin
Zhang, Bin
Moore, Yan
Wang, Haofei Tiffany
Kokhreidze, Jaba
Nazarenko, Natalya
Aix, Santiago Ponce
Bunn, Paul
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Hosp Univ 12 Octubre, Madrid, Spain
[3] Canc & Hematol Ctr Western Michigan, Grand Rapids, MI USA
[4] Inst Catala Oncol, Barcelona, Spain
[5] Hosp Univ & Politecn La Fe, Valencia, Spain
[6] Canc Treatment Ctr Amer, Atalanta, GA USA
[7] South West Healthcare, Warrnambool, Vic, Australia
[8] Hosp Reg Univ Malaga, Malaga, Spain
[9] Hosp Univ Virgen Del Rocio, Seville, Spain
[10] Hosp Univ Vall dHebron, Barcelona, Spain
[11] Case Western Reserve Univ, Cleveland, OH 44106 USA
[12] Univ Colorado, Denver, CO 80202 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9069
引用
收藏
页数：2
相关论文
共 36 条
  • [1] Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity
    Spigel, D. R.
    Paz-Ares, L. G.
    Chen, Y.
    Jove, M.
    Juan-Vidal, O.
    Rich, P.
    Hayes, T.
    Calderon, V. G.
    Caro, R. B.
    Navarro, A.
    Dowlati, A.
    Zhang, B.
    Moore, Y.
    Wang, T.
    Nazarenko, N.
    Kokhreidze, J.
    Ponce, S.
    Bunn, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S32 - S32
  • [2] RESILIENT part II: an open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy.
    Paz-Ares, Luis G.
    Spigel, David R.
    Chen, Yuanbin
    Jove, Maria
    Juan-Vidal, Oscar
    Rich, Patricia
    Hayes, Theresa M.
    Calderon, M. Vanesa Gutierrez
    Caro, Reyes Bernabe
    Navarro, Alejandro
    Dowlati, Afshin
    Zhang, Bin
    Moore, Yan
    Wang, Haofei Tiffany
    Kokhreidze, Jaba
    Aix, Santiago Ponce
    Bunn, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [3] Liposomal Irinotecan vs Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed On/After Platinum-Based Therapy
    Paz-Ares, L.
    Yang, J. C.
    Zielinski, C.
    Novello, S.
    Schwartsmann, G.
    Spigel, D.
    Griesinger, F.
    Dowlati, A.
    Small, T.
    De Jong, F.
    Zhang, B.
    Nazarenko, N.
    Bunn, P., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S791 - S792
  • [4] CILENGITIDE COMBINED WITH CETUXIMAB AND PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT IN ADVANCED NON-SMALL CELL LUNG CANCER: SAFETY RUN-IN RESULTS OF AN OPEN-LABEL, RANDOMIZED, PHASE II (CERTO) STUDY
    Vansteenkiste, J.
    Waller, C.
    Germonpre, P.
    Bohnet, S.
    Thatcher, N.
    Rueeter, B.
    Picard, M.
    Schuette, W.
    ANNALS OF ONCOLOGY, 2010, 21 : 177 - 177
  • [5] Cemiplimab with platinum-based chemotherapy (chemo) for first-line (1L) locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 3 subgroup analysis
    Kalinka-Warzocha, E.
    Gogishvili, M.
    Makharadze, T.
    Dvorkin, M.
    Penkov, K. D.
    Laktionov, K.
    Nechaeva, M.
    Rozhkova, I.
    He, X.
    Quek, R.
    Pouliot, J-F.
    Seebach, F.
    Lowy, I.
    Gullo, G.
    Rietschel, P.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S983 - S984
  • [6] CABAZITAXEL (CBZ) VS TOPOTECAN (TPT) IN PATIENTS (PTS) WITH SMALL CELL LUNG CANCER (SCLC) WITH PROGRESSIVE DISEASE DURING/AFTER FIRST-LINE (1L) TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY (CTX)
    Evans, T.
    Cho, B. C.
    Udud, K.
    Fischer, J. R.
    Shepherd, F. A.
    Martinez, P.
    Ramlau, R.
    Syrigos, K. N.
    Chadjaa, M.
    Wolf, M.
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : S28 - S29
  • [7] ORIENTAL: An open label, multicenter, phase IIIb study of first-line durvalumab plus platinum-based chemotherapy in Chinese patients with extensive stage small cell lung cancer (ES-SCLC)
    Cheng, Y.
    Wang, J.
    Cang, S.
    Cao, L.
    Chen, E.
    Dong, X.
    Fan, Y.
    Gao, B.
    Guo, Q.
    Huang, D.
    Li, S.
    Liu, A.
    Lv, D.
    Pan, Y.
    Tang, K.
    Yao, W.
    Ye, F.
    Yu, Y.
    Zang, A.
    Gao, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S727 - S728
  • [8] CheckMate 331: An open-label, randomized phase III trial of nivolumab versus chemotherapy in patients (pts) with relapsed small cell lung cancer (SCLC) after first-line platinum-based chemotherapy (PT-DC).
    Horn, Leora
    Reck, Martin
    Gettinger, Scott N.
    Spigel, David R.
    Antonia, Scott Joseph
    Rupnow, Brent A.
    Pieters, Anne
    Selvaggi, Giovanni
    Fairchild, Justin P.
    Peters, Solange
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Liposomal irinotecan (Lipo-IRI) alone or in combination with famitinib or platinum for patients with extensive-stage small cell lung cancer (ES-SCLC) after failure of first-line immunotherapy: A multicenter, randomized, open-label, multicohort phase II trial
    Xu, H.
    Shi, H.
    Jiang, W.
    Yang, Y.
    Lei, S. Y.
    Tian, L.
    Sun, R.
    Zhang, C.
    Nan, S.
    Wang, Y.
    ANNALS OF ONCOLOGY, 2024, 35
  • [10] First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
    Soria, Jean-Charles
    Tan, Daniel S. W.
    Chiari, Rita
    Wu, Yi-Long
    Paz-Ares, Luis
    Wolf, Juergen
    Geater, Sarayut L.
    Orlov, Sergey
    Cortinovis, Diego
    Yu, Chong-Jen
    Hochmair, Maximillian
    Cortot, Alexis B.
    Tsai, Chun-Ming
    Moro-Sibilot, Denis
    Campelo, Rosario G.
    McCulloch, Tracey
    Sen, Paramita
    Dugan, Margaret
    Pantano, Serafino
    Branle, Fabrice
    Massacesi, Cristian
    de Castro, Gilberto, Jr.
    LANCET, 2017, 389 (10072): : 917 - 929
1234